Get the Stockscreener App
1.52
0.66%
0.01
After Hours:
1.53
0.01
+0.66%
Atossa Therapeutics Inc stock is traded at $1.52, with a volume of 709.95K.
It is up +0.66% in the last 24 hours and up +10.95% over the past month.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
See More
Previous Close:
$1.51
Open:
$1.52
24h Volume:
709.95K
Relative Volume:
0.76
Market Cap:
$191.78M
Revenue:
-
Net Income/Loss:
$-29.69M
P/E Ratio:
-6.08
EPS:
-0.25
Net Cash Flow:
$-18.64M
1W Performance:
+7.80%
1M Performance:
+10.95%
6M Performance:
-15.56%
1Y Performance:
+106.38%
1-Day Range:
$1.49
$1.58
1-Week Range:
$1.35
$1.58
52-Week Range:
$0.62
$2.31
Atossa Therapeutics Inc Stock (ATOS) Company Profile
Name
Atossa Therapeutics Inc
Sector
Industry
Phone
206.588.0256
Address
10202 5TH AVENUE NE, SEATTLE, WA
Atossa Therapeutics Inc Stock (ATOS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-18 | Initiated | Maxim Group | Buy |
Atossa Therapeutics Inc Stock (ATOS) Latest News
Rhumbline Advisers Makes New $161,000 Investment in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
Was Atossa Therapeutics Inc (ATOS)’s session last reading good? - US Post News
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Acquired by Bank of New York Mellon Corp - MarketBeat
Atossa Therapeutics, Inc. (NASDAQ:ATOS) Shares Acquired by Bank of New York Mellon Corp - Defense World
Atossa Therapeutics Inc [ATOS] Investment Guide: What You Need to Know - Knox Daily
What Has Been Going On With Atossa Therapeutics Inc (NASDAQ: ATOS) - Stocks Register
Atossa Therapeutics Inc (ATOS) can make a big difference with a little luck - SETE News
Atossa Therapeutics (NASDAQ:ATOS) Shares Pass Above Two Hundred Day Moving Average of $1.41 - MarketBeat
Is Atossa Genetics (ATOS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
What is the investor’s view on Atossa Therapeutics Inc (ATOS)? - US Post News
Potential Price Increase for Atossa Therapeutics Inc (ATOS) After Recent Insider Activity - Knox Daily
Ratios Reveal: Breaking Down Atossa Therapeutics Inc (ATOS)’s Financial Health - The Dwinnex
Atossa Therapeutics Inc: Weathering Stock Market Storms with 182.35M Market Cap - The InvestChronicle
Taking on analysts’ expectations and winning: Atossa Therapeutics Inc (ATOS) - SETE News
Examining Atossa Therapeutics Inc (ATOS) stock is warranted - US Post News
Atossa Therapeutics (NASDAQ:ATOS) Price Target Increased to $6.50 by Analysts at Ascendiant Capital Markets - Defense World
Analyzing Atossa Therapeutics Inc (ATOS) After Recent Trading Activity - Knox Daily
Atossa Therapeutics (NASDAQ:ATOS) Price Target Raised to $6.50 - MarketBeat
Atossa Therapeutics Inc’s Shares Reel: 21.67% Quarterly Revenue Decline Amid 183.61M Market Cap - The InvestChronicle
Atossa Therapeutics Announces Support of Final Rule from FDA Requiring Patient Notification of Breast Density, a Critical Step in Addressing a Known Risk Factor for Breast Cancer - StockTitan
Atossa Therapeutics (NASDAQ:ATOS) Share Price Passes Below 200-Day Moving Average of $1.38 - MarketBeat
Are Atossa Therapeutics Inc (ATOS) shares a good deal now? - US Post News
Is Atossa Genetics (ATOS) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Atossa Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference - StockTitan
Recent Insider Activity Suggests Potential Gains for Atossa Therapeutics Inc (ATOS) - Knox Daily
Are You Looking for a Top Momentum Pick? Why Atossa Genetics Inc. (ATOS) is a Great Choice - Yahoo Finance
Dow Jones Industrials Average (DOWI) QuotePress Release - The Globe and Mail
TSX Materials Capped Index (TTMT) QuotePress Release - The Globe and Mail
Atossa Therapeutics Inc (ATOS-Q) QuotePress Release - The Globe and Mail
Atossa secures new patent for breast cancer drug By Investing.com - Investing.com Canada
Atossa secures new patent for breast cancer drug - Investing.com
Nothing is Better Than Atossa Therapeutics Inc (ATOS) stock at the moment - SETE News
Atossa secures new patent for breast cancer drug By Investing.com - Investing.com UK
Atossa Therapeutics Granted Additional Patent Protection for Endoxifen - Yahoo Canada Finance
Atossa Therapeutics Inc (ATOS) Stock: A Comprehensive 52-Week Review - The InvestChronicle
TSX Utilities Capped Index (TTUT) QuotePress Release - The Globe and Mail
Can you now get a good deal on Atossa Therapeutics Inc’s shares? - US Post News
The Potential Rise in the Price of Atossa Therapeutics Inc (ATOS) following insiders activity - Knox Daily
Financial Comparison: Atossa Therapeutics (NASDAQ:ATOS) versus Renovaro (NASDAQ:RENB) - Defense World
When Can We Expect A Profit From Atossa Therapeutics, Inc. (NASDAQ:ATOS)? - Simply Wall St
Atossa and Quantum Leap begin breast cancer treatment trial - Investing.com India
Understanding the Risks of Investing in Atossa Therapeutics Inc (ATOS) - Knox Daily
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer - ForexTV.com
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer - Yahoo Finance
Atossa and Quantum Leap begin breast cancer treatment trial By Investing.com - Investing.com Australia
Atossa and Quantum Leap begin breast cancer treatment trial - Investing.com
Atossa Therapeutics and Quantum Leap Healthcare Collaborative Dose First Patient in I-SPY 2 Trial Combining (Z)-Endoxifen with Abemaciclib for ER+/HER2- Breast Cancer - StockTitan
Atossa Therapeutics Announces the Appointment of Michael Parks as Vice President, Investor and Public Relations - StockTitan
Cetera Advisors LLC Takes $72,000 Position in Atossa Therapeutics, Inc. (NASDAQ:ATOS) - Defense World
FY2024 Earnings Estimate for Atossa Therapeutics, Inc. (NASDAQ:ATOS) Issued By Cantor Fitzgerald - Defense World
FY2024 EPS Estimates for Atossa Therapeutics, Inc. Lifted by Analyst (NASDAQ:ATOS) - MarketBeat
Atossa Therapeutics Inc Stock (ATOS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):